David Myles, Ph.D. ’80 bridges the worlds of academia and business: After completing his Ph.D. at Yale and a postdoctoral fellowship at Harvard, he became an assistant professor in UCLA’s Department of Chemistry and Biochemistry. He subsequently turned to private industry, first with Chiron Corporation, later as executive director of Kosan Biosciences and cofounder and chief operating officer of Epiphany Biosciences. Myles is now executive vice president of drug development for San Francisco-based Olema Pharmaceuticals, focusing on the treatment of breast cancer. Although he sees himself “more as an entrepreneur than as a pure scientist,” he has at least 80 peer-reviewed papers and 17 issued patents to his credit, with more in process. Myles, who lives in Berkeley with his three children, first learned about Webb during a field trip to the Alf Museum in the sixth grade. He says Webb’s emphasis on independent thinking and personal integrity has served him well throughout his career. This is Myles’ third term on the board and he is pleased to see some of the long-term plans that originated in his earlier terms come to fruition. “It’s an unbelievable honor to be asked to serve again,” he says.
Sponsored by the Robert ’53 and MeiLi Hefner Foundation and offered here at Webb to two current students, The Hefner Initiative aims to foster a close and positive relationship between the people of China and the US. This extraordinary 12-day summer program includes travel this year to Beijing and Suzhou—allowing for living/learning opportunities with host students and families.
Shyam Arya '18 and Ellie Canty '18 have been accepted to present a poster at the National American Chemical Society conference in New Orleans in March 2019--an extremely rare honor for high school students.
It’s November 2nd and the College Guidance office is quiet this morning—nothing like the last few days when countless numbers of panicked seniors were popping in to get their essays looked at one last time before pressing “submit.”